Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
暂无分享，去创建一个
[1] F. Montorsi,et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study , 2021, The Lancet Rheumatology.
[2] G. Cavalli,et al. The right place for IL-1 inhibition in COVID-19 , 2021, The Lancet Respiratory Medicine.
[3] J. Callejas-Rubio,et al. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study , 2021, Internal and Emergency Medicine.
[4] A. Tomelleri,et al. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic , 2020, Frontiers in Pharmacology.
[5] C. Dinarello,et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19 , 2020, Proceedings of the National Academy of Sciences.
[6] G. Chatellier,et al. Anakinra for severe forms of COVID-19: a cohort study , 2020, The Lancet Rheumatology.
[7] A. Zangrillo,et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study , 2020, The Lancet Rheumatology.